Evidence map›Paper›PMID 38867495›Full record

ReviewPharmacology research & perspectives2024

Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination.

László G Boros, Anthony M Kyriakopoulos, Carlo Brogna, Marina Piscopo, Peter A McCullough, Stephanie Seneff

Abstract readReview
In one paragraph

Review in Pharmacology research & perspectives, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Zinc: a metallic shield against cardiac inflammation.Metallomics : integrated biometal science · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Characteristics of Oral Adverse Effects following COVID-19 Vaccination and Similarities with Oral Symptoms in COVID-19 Patients: Taste and Saliva Secretory Disorders.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

László G BorosSub-Molecular Medical Sciences Deutenomics Core, Vrije University Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0003-1211-9933
Anthony M KyriakopoulosDepartment of Research and Development, Nasco AD Biotechnology Laboratory, Piraeus, Greece.ORCID https://orcid.org/0000-0002-0749-0060
Carlo BrognaDepartment of Research, Craniomed Group Facility Srl, Italy.ORCID https://orcid.org/0000-0001-6252-0595
Marina PiscopoDepartment of Biology, University of Naples Federico II, Naples, Italy.ORCID https://orcid.org/0000-0003-0560-6952
Peter A McCulloughMcCullough Foundation, Dallas, Texas, USA.ORCID https://orcid.org/0000-0002-0997-6355
Stephanie SeneffComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0001-8191-1049

Funding

McCullough Foundation, Dallas TX, USA N/A - charitable US 501c3 organization
6 · The paper itself

Abstract

According to the CDC, both Pfizer and Moderna COVID-19 vaccines contain nucleoside-modified messenger RNA (mRNA) encoding the viral spike glycoprotein of severe acute respiratory syndrome caused by corona virus (SARS-CoV-2), administered via intramuscular injections. Despite their worldwide use, very little is known about how nucleoside modifications in mRNA sequences affect their breakdown, transcription and protein synthesis. It was hoped that resident and circulating immune cells attracted to the injection site make copies of the spike protein while the injected mRNA degrades within a few days. It was also originally estimated that recombinant spike proteins generated by mRNA vaccines would persist in the body for a few weeks. In reality, clinical studies now report that modified SARS-CoV-2 mRNA routinely persist up to a month from injection and can be detected in cardiac and skeletal muscle at sites of inflammation and fibrosis, while the recombinant spike protein may persist a little over half a year in blood. Vaccination with 1-methylΨ (pseudouridine enriched) mRNA can elicit cellular immunity to peptide antigens produced by +1 ribosomal frameshifting in major histocompatibility complex-diverse people. The translation of 1-methylΨ mRNA using liquid chromatography tandem mass spectrometry identified nine peptides derived from the mRNA +1 frame. These products impact on off-target host T cell immunity that include increased production of new B cell antigens with far reaching clinical consequences. As an example, a highly significant increase in heart muscle 18-flourodeoxyglucose uptake was detected in vaccinated patients up to half a year (180 days). This review article focuses on medical biochemistry, proteomics and deutenomics principles that explain the persisting spike phenomenon in circulation with organ-related functional damage even in asymptomatic individuals. Proline and hydroxyproline residues emerge as prominent deuterium (heavy hydrogen) binding sites in structural proteins with robust isotopic stability that resists not only enzymatic breakdown, but virtually all (non)-enzymatic cleavage mechanisms known in chemistry.

Indexed as

COVID-19COVID-19 VaccinesRNA, MessengerSpike Glycoprotein, CoronavirusHumansmRNA VaccinesPseudouridineRecombinant ProteinsRNA, ViralVaccinationVaccines, SyntheticCOVID-19 VaccinesmRNA VaccinesPseudouridineRecombinant ProteinsRNA, MessengerRNA, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, Syntheticacid hydrolysisdeutenomicsdeuteriumDNA polymerase thetahypoxiamodified mRNArecombinant spike proteinSARS‐CoV‐2

Identifiers

PMID38867495
PMCPMC11169277

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.